Morlock R - Search Results

1

Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial.

Feltner D, Hill C, Lenderking W, Williams V, Morlock R. Feltner D, et al. Among authors: morlock r. J Psychiatr Res. 2009 Oct;43(15):1224-30. doi: 10.1016/j.jpsychires.2009.04.001. Epub 2009 May 6. J Psychiatr Res. 2009. PMID: 19423131 Clinical Trial.

2

Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.

Feltner DE, Harness J, Brock J, Sambunaris A, Cappelleri JC, Morlock R. Feltner DE, et al. Among authors: morlock r. CNS Neurosci Ther. 2009 Winter;15(1):12-8. doi: 10.1111/j.1755-5949.2008.00075.x. CNS Neurosci Ther. 2009. PMID: 19228175 Free PMC article. Clinical Trial.

3

Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder.

Matza LS, Morlock R, Sexton C, Malley K, Feltner D. Matza LS, et al. Among authors: morlock r. Int J Methods Psychiatr Res. 2010 Dec;19(4):223-32. doi: 10.1002/mpr.323. Epub 2010 Aug 18. Int J Methods Psychiatr Res. 2010. PMID: 20718076 Free PMC article.

4

Development and evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder.

Morlock RJ, Williams VS, Cappelleri JC, Harness J, Fehnel SE, Endicott J, Feltner D. Morlock RJ, et al. J Psychiatr Res. 2008 Oct;42(12):1024-36. doi: 10.1016/j.jpsychires.2007.09.005. Epub 2007 Dec 3. J Psychiatr Res. 2008. PMID: 18061206

5

Psychometric evaluation of a visual analog scale for the assessment of anxiety.

Williams VS, Morlock RJ, Feltner D. Williams VS, et al. Health Qual Life Outcomes. 2010 Jun 8;8:57. doi: 10.1186/1477-7525-8-57. Health Qual Life Outcomes. 2010. PMID: 20529361 Free PMC article.

6

The patient experience of depression and remission: focus group results.

Frank L, Matza LS, Hanlon J, Mannix S, Revicki DA, Feltner D, Morlock RJ. Frank L, et al. J Nerv Ment Dis. 2007 Aug;195(8):647-54. doi: 10.1097/NMD.0b013e31811f400f. J Nerv Ment Dis. 2007. PMID: 17700296

7

Psychometric evaluation of the medical outcomes study-sleep scale in persons with overactive bladder.

Lau DT, Morlock RJ, Hill CD. Lau DT, et al. Clin Ther. 2006 Dec;28(12):2119-32. doi: 10.1016/j.clinthera.2006.12.008. Clin Ther. 2006. PMID: 17296468

8

Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia.

Alphs L, Morlock R, Coon C, Cazorla P, Szegedi A, Panagides J. Alphs L, et al. Among authors: morlock r. Int J Methods Psychiatr Res. 2011 Jun;20(2):e31-7. doi: 10.1002/mpr.339. Int J Methods Psychiatr Res. 2011. PMID: 21538654 Free PMC article.

9

Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia.

Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Velligan DI, et al. Among authors: morlock r. Psychiatry Res. 2009 Sep 30;169(2):97-100. doi: 10.1016/j.psychres.2008.10.009. Epub 2009 Aug 7. Psychiatry Res. 2009. PMID: 19664826

10

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.

Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, Ramaswamy K, Ivanescu C, Attard G. Tombal B, et al. Among authors: morlock r. Lancet Oncol. 2019 Apr;20(4):556-569. doi: 10.1016/S1470-2045(18)30898-2. Epub 2019 Feb 12. Lancet Oncol. 2019. PMID: 30770294 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters